SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF
The present invention relates to siRNA molecules targeting a SLC10A1 mRNA transcript and methods of using the siRNA compositions for treatment of a NTCP associated disorder.
1 . A small interfering RNA (siRNA) molecule targeting a SLC10A1 mRNA transcript, comprising a double-stranded region of 17- to 30-base pairs in length that is formed between the complementary base pairs of a sense strand sequence and an antisense strand sequence, wherein the siRNA comprises a sense strand sequence selected from the group consisting of SEQ ID Nos. 1-15, 31-45 and 481-611, and/or an antisense strand sequence selected from the group consisting of SEQ ID Nos. 16-30, 46-60 and 612-742.
2 . (canceled)
3 . The siRNA molecule of claim 1 , wherein the sequence of the siRNA molecule has 100% complementary, or a mismatch of 4 base pairs or fewer to a portion of the sequence of the SLC10A1 mRNA transcript.
4 .- 5 . (canceled)
6 . The siRNA molecule of claim 1 , wherein the siRNA molecule targets a human SLC10A1 mRNA transcript.
7 .- 9 . (canceled)
10 . The siRNA molecule of claim 1 , wherein the siRNA molecule comprises at least one overhang, each overhang having up to six or fewer nucleotides.
11 .- 16 . (canceled)
17 . The siRNA molecule of claim 1 , wherein the siRNA comprises one or more chemical modifications, and wherein the one or more chemical modifications is 2′-O-methyl modification, 2′-fluoro modification, introduction of phosphorothioate modified nucleotides, substitution of uracil with 5-Propynyluracil, substitution of uracil with 5′-methyluridine, substitution of uracil ribose nucleotides with 4′-thioribose and substitution of uracil ribose nucleotides with deoxythymidine nucleotides, or any combinations thereof.
18 .- 21 . (canceled)
22 . The siRNA molecule of claim 17 , wherein the chemical modifications include at least one 2′-O-methyl modification and/or at least one 2′-fluoro modification.
23 .- 24 . (canceled)
25 . The siRNA molecule of claim 1 , wherein the siRNA is conjugated to at least one N-acetylgalactosamine (GalNAc) moiety or derivative thereof.
26 . (canceled)
27 . The siRNA molecule of claim 25 , wherein the GalNAc moiety is conjugated to the 3′ end of the sense strand.
28 .- 29 . (canceled)
30 . The siRNA molecule of claim 17 , wherein the siRNA comprises a sense strand sequence selected from the group consisting of SEQ ID Nos. 61-270 and 743-873, and/or an antisense strand sequence selected from the group consisting of SEQ ID Nos. 271-480 and 874-1004.
31 . The siRNA molecule of claim 30 , comprising a pair of sense and antisense strand sequences selected from the group consisting of the pairs of SEQ ID NOs. 95 and 305; SEQ ID NOs. 110 and 320; SEQ ID NOs. 121 and 331; SEQ ID NOs. 125 and 335; SEQ ID NOs. 143 and 353; SEQ ID NOs. 181 and 391; SEQ ID NOs. 200 and 410; SEQ ID NOs. 215 and 425.
32 . A pharmaceutical composition comprising the siRNA molecule according to claim 1 , and a pharmaceutically acceptable excipient or carrier.
33 .- 34 . (canceled)
35 . A method of treating a cholestatic disorder in a patient in need thereof comprising administering to the patient a siRNA molecule targeting a human SLC10A1 mRNA transcript, comprising a pair of a sense strand sequence and an antisense strand sequence, wherein the siRNA comprises a sense strand sequence selected from the group consisting of SEQ ID Nos. 1-15, 31-45, 61-270, 481-611, and 743-873, and/or an antisense strand sequence selected from the group consisting of SEQ ID Nos. 16-30, 46-60 271-480, 612-742, and 874-1004.
36 . The method of claim 35 , wherein the cholestatic disorder is progressive intrahepatic familial cholestasis (PFIC), Alagille syndrome (ALGS), biliary atresia (BA), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), or intrahepatic cholestasis of pregnancy (ICP), or cholestasis caused by another disease or procedure, such as cholestasis after liver transplantation or cholestasis from a malignant biliary obstruction.
37 . (canceled)
38 . A method of treating in a patient in need comprising administering to the patient the siRNA molecule of claim 1 , wherein the patient has liver damage, including inflammation, fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma.
39 .- 42 . (canceled)
43 . A method of treating a disease that is associated with bile acid transporter, sodium taurocholate co-transporting polypeptide (NTCP), comprising silencing or reducing expression of a human SLC10A1 mRNA transcript with the siRNA molecule of claim 1 .
44 . The method of claim 43 , wherein the disease is a cholestatic disorder, hepatitis B, hepatitis D, MASLD, MASH, MetALD (also known as NAFLD or NASH), diabetes, obesity, dyslipidemia, inflammatory bowel disease, or constipation inflammatory bowel disease (IBD).
45 .- 48 . (canceled)
49 . A method for reducing expression of a SLC10A1 mRNA transcript in a cell comprising administering the siRNA of claim 1 .
50 .- 51 . (canceled)
52 . The siRNA molecule of claim 1 comprising a pair of a modified sense strand sequence and a modified anti-sense strand sequence listed in Table 3, Table 5 and Table 6.
53 .- 56 . (canceled)
57 . A method of treating a viral hepatitis B and/or hepatitis D disease in a subject using a siRNA targeting a human SLC10A1 mRNA transcript, comprising a pair of a sense strand sequence and an antisense strand sequence as a monotherapy or in a regimen combination with one or more antiviral agents, wherein the siRNA comprises a sense strand sequence selected from the group consisting of SEQ ID Nos. 1-15, 31-45, 61-270, 481-611, and 743-873, and/or an antisense strand sequence selected from the group consisting of SEQ ID Nos. 16-30, 46-60 271-480, 612-742, and 874-1004.
58 .- 70 . (canceled)
71 . The siRNA molecule of claim 31 , comprising a sense strand sequence of SEQ ID NO. 110 and an antisense strand sequence of SEQ ID NO. 320, and wherein the siRNA comprises at least one GalNAc moiety or derivative thereof.
72 .- 77 . (canceled)